+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Progressive Supranuclear Palsy (PSP) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749281
  • Report
  • 65 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AlzProtect SAS
  • Asceneuron SA
  • Cortice Biosciences Inc
  • K-Stemcell Co Ltd
  • Prana Biotechnology Ltd
  • MORE
The global demand for Progressive Supranuclear Palsy (PSP) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Progressive Supranuclear Palsy (PSP) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Progressive Supranuclear Palsy (PSP) pipeline companies from advancing their products into Phase 3 or Phase 4.

Progressive Supranuclear Palsy (PSP) Report Description

The 2019 pipeline study on Progressive Supranuclear Palsy (PSP) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Progressive Supranuclear Palsy (PSP) pipeline compounds.

The Progressive Supranuclear Palsy (PSP) pipeline guide presents information on all active drugs currently being developed for Progressive Supranuclear Palsy (PSP). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Progressive Supranuclear Palsy (PSP) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Progressive Supranuclear Palsy (PSP) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Progressive Supranuclear Palsy (PSP) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Progressive Supranuclear Palsy (PSP) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Progressive Supranuclear Palsy (PSP) pipeline report includes
  • An overview of Progressive Supranuclear Palsy (PSP) disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Progressive Supranuclear Palsy (PSP) pipeline
  • Company wise list of Progressive Supranuclear Palsy (PSP) pipeline
  • Mechanism of Action wise Progressive Supranuclear Palsy (PSP) pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Progressive Supranuclear Palsy (PSP) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Progressive Supranuclear Palsy (PSP) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Progressive Supranuclear Palsy (PSP) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AlzProtect SAS
  • Asceneuron SA
  • Cortice Biosciences Inc
  • K-Stemcell Co Ltd
  • Prana Biotechnology Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Progressive Supranuclear Palsy (PSP) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Progressive Supranuclear Palsy (PSP) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Progressive Supranuclear Palsy (PSP) pipeline, H1- 2019
3.5 Mechanism of Action wise Progressive Supranuclear Palsy (PSP) Pipeline Candidates

4 AbbVie Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Progressive Supranuclear Palsy (PSP) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 AC Immune Progressive Supranuclear Palsy (PSP) Pipeline Details
5.1 AC Immune Business Profile
5.2 AC Immune Progressive Supranuclear Palsy (PSP) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 AlzProtect SAS Progressive Supranuclear Palsy (PSP) Pipeline Details
6.1 AlzProtect SAS Business Profile
6.2 AlzProtect SAS Progressive Supranuclear Palsy (PSP) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Aquinnah Pharmaceuticals Progressive Supranuclear Palsy (PSP) Pipeline Details
7.1 Aquinnah Pharmaceuticals Business Profile
7.2 Aquinnah Pharmaceuticals Progressive Supranuclear Palsy (PSP) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Asceneuron SA Progressive Supranuclear Palsy (PSP) Pipeline Details
8.1 Asceneuron SA Business Profile
8.2 Asceneuron SA Progressive Supranuclear Palsy (PSP) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Biogen Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
9.1 Biogen Inc Business Profile
9.2 Biogen Inc Progressive Supranuclear Palsy (PSP) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Cortice Biosciences Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
10.1 Cortice Biosciences Inc Business Profile
10.2 Cortice Biosciences Inc Progressive Supranuclear Palsy (PSP) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Declion Pharmaceuticals Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
11.1 Declion Pharmaceuticals Inc Business Profile
11.2 Declion Pharmaceuticals Inc Progressive Supranuclear Palsy (PSP) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Delta Crystallon BV Progressive Supranuclear Palsy (PSP) Pipeline Details
12.1 Delta Crystallon BV Business Profile
12.2 Delta Crystallon BV Progressive Supranuclear Palsy (PSP) Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Intellect Neurosciences Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
13.1 Intellect Neurosciences Inc Business Profile
13.2 Intellect Neurosciences Inc Progressive Supranuclear Palsy (PSP) Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 K-Stemcell Co Ltd Progressive Supranuclear Palsy (PSP) Pipeline Details
14.1 K-Stemcell Co Ltd Business Profile
14.2 K-Stemcell Co Ltd Progressive Supranuclear Palsy (PSP) Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Merck & Co Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
15.1 Merck & Co Inc Business Profile
15.2 Merck & Co Inc Progressive Supranuclear Palsy (PSP) Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Prana Biotechnology Ltd Progressive Supranuclear Palsy (PSP) Pipeline Details
16.1 Prana Biotechnology Ltd Business Profile
16.2 Prana Biotechnology Ltd Progressive Supranuclear Palsy (PSP) Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Prothena Corp Plc Progressive Supranuclear Palsy (PSP) Pipeline Details
17.1 Prothena Corp Plc Business Profile
17.2 Prothena Corp Plc Progressive Supranuclear Palsy (PSP) Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 TauRx Therapeutics Ltd Progressive Supranuclear Palsy (PSP) Pipeline Details
18.1 TauRx Therapeutics Ltd Business Profile
18.2 TauRx Therapeutics Ltd Progressive Supranuclear Palsy (PSP) Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 UCB SA Progressive Supranuclear Palsy (PSP) Pipeline Details
19.1 UCB SA Business Profile
19.2 UCB SA Progressive Supranuclear Palsy (PSP) Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 Voyager Therapeutics Inc Progressive Supranuclear Palsy (PSP) Pipeline Details
20.1 Voyager Therapeutics Inc Business Profile
20.2 Voyager Therapeutics Inc Progressive Supranuclear Palsy (PSP) Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21. Latest Progressive Supranuclear Palsy (PSP) Drug Pipeline Developments, 2019

22. Appendix
22.1 About Us
22.2 Sources and Methodology
22.3 Contact Information
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • AC Immune
  • AlzProtect SAS
  • Aquinnah Pharmaceuticals
  • Asceneuron SA
  • Biogen Inc
  • Cortice Biosciences Inc
  • Declion Pharmaceuticals Inc
  • Delta Crystallon BV
  • Intellect Neurosciences Inc
  • K-Stemcell Co Ltd
  • Merck & Co Inc
  • Prana Biotechnology Ltd
  • Prothena Corp Plc
  • TauRx Therapeutics Ltd
  • UCB SA
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4749281
Adroll
adroll